While Gleevec is a big opportunity, Sun has a strong pipeline of 184 Abbreviated New Drug applications, likely to fuel growth in the coming years. Analysts at Ambit Capital estimate a 19 per cent growth over FY14E-18E (including Ranbaxy). Rest of the World market revenues, according to them are likely to grow 53 per cent, including Ranbaxy, led by synergies between Ranbaxy's platform and Sun's product portfolio. They add that continued earnings momentum (22 per cent FY14-16E compounded annual growth rate) and high return on capital employed would support rich valuations. However in the near term, the Street will take cues from the company's March quarter performance. Analysts expect the company's base to sustain previous quarter levels or improve marginally.